Sec Form 13D Filing - ABBOTT LABORATORIES (ABT) filing for Mylan II B.V. (MYL) - 2017-03-24

Under the Securities Exchange Act of 1934
(Amendment No. 5)

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)

With a copy to:

(Date of Event Which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box o.

2

3

4

Item 1.         Security and Issuer.

This Amendment No. 5 to Schedule 13D (this “Amendment No. 5”) relates to the ordinary shares, nominal value €0.01 per share (the “Ordinary Shares”), of Mylan N.V., a public limited company (naamloze vennootschap) incorporated under the laws of the Netherlands (the “Issuer”), and amends the Statement on Schedule 13D filed by Abbott Laboratories and certain of its subsidiaries on March 6, 2015, as amended as of April 6, 2015, April 10, 2015, June 18, 2015 and August 10, 2015 (as so amended, the “Initial Statement”). Except as specifically provided herein, this Amendment No. 5 does not modify any of the information previously reported in the Initial Statement. Capitalized terms used but not defined in this Amendment No. 5 have the respective meanings set forth in the Initial Statement.

Item 5.         Interest in Securities of the Issuer.

This Amendment No. 5 amends Item 5 of the Initial Statement by inserting the following after the last paragraph of Item 5:

“On March 23, 2017, the Reporting Persons sold a total of 44,000,000 Ordinary Shares through a privately-negotiated block trade  pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended, at a price of $41.60 per Ordinar y Share, not including discounts and commission.  Following completion of the sale transaction, the Reporting Persons beneficially own an aggregate of 25,750,000 Ordinary Shares, representing approximately 4.81% of the outstanding Ordinary Shares. The foregoing percentage beneficial ownership is based on a total of 535,496,988 Ordinary Shares outstanding as of February 24, 2017, as reported by the Issuer in its Annual Report on Form 10-K for the fiscal year ended December 31, 2016.”

5

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 23, 2017

6